Clinical Trial: Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment

U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07238881) titled 'Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment' on Nov. 16.

Brief Summary: While immune-based therapies (including targeted-immune or dual-immune regimens) have become first-line standard for advanced hepatocellular carcinoma (HCC), there is a lack of high-level evidence to guide second-line treatment after progression on immune checkpoint inhibitors (ICIs).

Preclinical studies suggest synergistic antitumor activity between CDK4/6 inhibitors and PD-1/PD-L1 blockade. However, no clinical studies have yet evaluated the combination of dalpiciclib and camrelizumab in this setting.

To address ...